Celsis International is a leading provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries worldwide through its three business areas, featuring rapid microbial detection systems, analytical laboratory services and in vitro ADME-Tox products. Each Celsis division delivers substantial time and cost savings to customers in addition to ensuring product quality and safety for consumers. Founded in Cambridge, England (UK), by Sir Christopher Evans, Celsis was listed on the London Stock Exchange from 1993 until October 2009, when it was purchased by J O Hambro Capital Management Group. Headquartered in Chicago with major facilities in the U.S. and Europe, Celsis employs more than 200 people worldwide.
